Short Interest in Briacell Therap (NASDAQ:BCTX) Expands By 81.5%

Briacell Therap (NASDAQ:BCTX) saw a large increase in short interest in August. As of August 31st, there was short interest totaling 723,836 shares, an increase of 81.5% from the August 15th total of 398,913 shares. Based on an average daily volume of 967,776 shares, the short-interest ratio is currently 0.7 days. Approximately 8.4% of the company’s stock are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Briacell Therap in a research report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Briacell Therap Trading Down 1.6%

NASDAQ:BCTX opened at $3.52 on Wednesday. The firm has a market capitalization of $30.63 million, a PE ratio of -0.44 and a beta of 1.10. The stock has a 50 day moving average of $3.62 and a 200-day moving average of $3.71. Briacell Therap has a 52 week low of $2.60 and a 52 week high of $14.68.

Briacell Therap Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.